Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study

International Journal of Cardiology

Volumn 167, Issue 5, 2013, Pages 2018-2023

  Siller Matula, Jolanta M ^a   Francesconi, Marcel ^b   Dechant, Cornelia ^b   Jilma, Bernd ^a   Maurer, Gerald ^a   Delle Karth, Georg ^a   Gouya, Ghazaleh ^b   Ruzicka, Katharina ^b   Podczeck Schweighofer, Andrea ^b   Christ, Günter ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

Acute coronary syndrome; Clopidogrel; Personalized treatment; Platelets; Stent thrombosis

Indexed keywords

CLOPIDOGREL; PRASUGREL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPEATED DRUG DOSE; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; UROGENITAL TRACT DISEASE;

ACUTE CORONARY SYNDROME; CLOPIDOGREL; PERSONALIZED TREATMENT; PLATELETS; STENT THROMBOSIS;

AGED; AGED, 80 AND OVER; COHORT STUDIES; ELECTRODES, IMPLANTED; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84883263516     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.05.040     Document Type: Article

References (51)

1. T. Geisler, M. Gawaz, S.R. Steinhubl, D.L. Bhatt, R.F. Storey, and M. Flather Current strategies in antiplatelet therapy - does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease? Pharmacol Ther 127 2 2010 95 107
2. K.K. Mangalpally, and N.S. Kleiman The safety of clopidogrel Expert Opin Drug Saf 10 1 2011 85 95
3. J.M. Siller-Matula, J. Krumphuber, and B. Jilma Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular disease Br J Pharmacol 159 3 2009 502 517
4. P.A. Gurbel, A.R. Shuldiner, K.P. Bliden, K. Ryan, R.E. Pakyz, and U.S. Tantry The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy Am Heart J 161 3 2011 598 604
5. L. Yukhanyan, M.K. Freynhofer, J. Siller-Matula, K. Schror, and K. Huber Genetic variability in response to clopidogrel therapy and its clinical implications Thromb Haemost 105 Suppl. 1 2011 S55 S59
6. I. Tentzeris, J. Siller-Matula, S. Farhan, R. Jarai, J. Wojta, and K. Huber Platelet function variability and non-genetic causes Thromb Haemost 105(99) Suppl. 1 2011 S60 6
7. P.A. Gurbel, M.J. Antonino, and K.P. Bliden Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target Platelets 19 8 2008 595 604
8. D. Aradi, A. Komocsi, and A. Vorobcsuk Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis Am Heart J 160 3 2010 543 551
9. D. Sibbing, S. Braun, and T. Morath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
10. T. Geisler, C. Zurn, and R. Simonenko Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions Eur Heart J 31 1 2010 59 66
11. J.M. Siller-Matula, G. Christ, I.M. Lang, G. Delle-Karth, K. Huber, and B. Jilma Multiple electrode aggregometry predicts stent thrombosis better than the VASP assay J Thromb Haemost 8 2 2010 351 359
12. K. Schror, J.M. Siller-Matula, and K. Huber Pharmacokinetic basis of the antiplatelet action of prasugrel Fundam Clin Pharmacol 26 1 2011 39 46
13. J.M. Siller-Matula, and B. Jilma Ticagrelor: from discovery to clinical trial phase III Future Cardiol 6 6 2010 753 764
14. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 11 2009 1045 1057
15. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 20 2007 2001 2015
16. J.A. Jakubowski, J.S. Riesmeyer, S.L. Close, A.G. Leishman, and D. Erlinge TRITON and beyond: new insights into the profile of prasugrel Cardiovasc Ther 30 4 2012 e174 e182
17. E.P. Navarese, M. Verdoia, and A. Schaffer Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials QJM 104 7 2011 561 569
18. L. Bonello, L. Camoin-Jau, and S. Armero Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis Am J Cardiol 103 1 2009 5 10
19. E.P. Navarese, G. De Luca, F. Castriota, M. Kozinski, P. Gurbel, C.M. Gibson, F. Andreotti, A. Buffon, J.M. Siller-Matula, A. Sukiennik, S. De Servi, and J. Kubica Low-molecular-weight heparins vs unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis J Thromb Haemost 9 10 2011 1902 1915
20. J.M. Siller-Matula, G. Gouya, M. Wolzt, and B. Jilma Cross validation of the multiple electrode aggregometry. A prospective trial in healthy volunteers Thromb Haemost 102 2 2009 397 403
21. J.M. Siller-Matula, K. Haberl, K. Prillinger, S. Panzer, I. Lang, and B. Jilma The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation Thromb Res 123 6 2009 874 880
22. J.M. Siller-Matula, I. Lang, G. Christ, and B. Jilma Calcium-channel blockers reduce the antiplatelet effect of clopidogrel J Am Coll Cardiol 52 19 2008 1557 1563
23. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 17 2007 2344 2351
24. J.S. Alpert, K. Thygesen, A. Jaffe, and H.D. White The universal definition of myocardial infarction: a consensus document: ischaemic heart disease Heart 94 10 2008 1335 1341
25. J.P. Bassand, and C. Hamm New European guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction - what are the new and key messages Pol Arch Med Wewn 117 9 2007 391 393
26. P.G. Steg, K. Huber, and F. Andreotti Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology Eur Heart J 32 15 2011 1854 1864
27. N. von Beckerath, A. Kastrati, and A. Wieczorek A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days Eur Heart J 28 15 2007 1814 1819
28. D.J. Angiolillo, E. Bernardo, and M. Sabate Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease J Am Coll Cardiol 50 16 2007 1541 1547
29. D.J. Angiolillo, E. Bernardo, and J. Palazuelos Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study Thromb Haemost 99 1 2008 161 168
30. L. Bonello, L. Camoin-Jau, and S. Arques Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 14 2008 1404 1411
31. S. Matetzky, P. Fefer, B. Shenkman, D. Varon, N. Savion, and H. Hod Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction Am J Cardiol 102 5 2008 524 529
32. B. Aleil, L. Jacquemin, and F. De Poli Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study JACC Cardiovasc Interv 1 6 2008 631 638
33. J.P. Collet, J.S. Hulot, and G. Anzaha High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2) JACC Cardiovasc Interv 4 4 2011 392 402
34. Y.H. Jeong, S.W. Lee, and B.R. Choi Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study J Am Coll Cardiol 53 13 2009 1101 1109
35. P.A. Gurbel, K.P. Bliden, and M.J. Antonino The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients J Thromb Haemost 8 1 2010 43 53
36. P.A. Gurbel, K.P. Bliden, and K. Butler Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 121 10 2010 1188 1199
37. J.T. Brandt, C.D. Payne, and S.D. Wiviott A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 1 2007 66 [e9-16]
38. M. Valgimigli, G. Campo, and N. de Cesare Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study Circulation 119 25 2009 3215 3222
39. T. Cuisset, C. Frere, and J. Quilici Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study JACC Cardiovasc Interv 1 6 2008 649 653
40. M.J. Price, P.B. Berger, and P.S. Teirstein Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 11 2011 1097 1105
41. D. Sibbing, S. Schulz, and S. Braun Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement J Thromb Haemost 8 2 2010 250 256
42. D. Sibbing, S.R. Steinhubl, S. Schulz, A. Schomig, and A. Kastrati Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window J Am Coll Cardiol 56 4 2010 317 318
43. J.M. Siller-Matula, G. Delle-Karth, and G. Christ Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin Int J Cardiol 167 2 2013 430 435
44. J.M. Siller-Matula, G. Delle-Karth, and I.M. Lang Phenotyping versus genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study J Thromb Haemost 10 4 2012 529 542
45. G. Pare, S.R. Mehta, and S. Yusuf Effects of CYP2C19 genotype on outcomes of clopidogrel treatment N Engl J Med 363 18 2010 1704 1714
46. L. Wallentin, S. James, and R.F. Storey Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 9749 2010 1320 1328
47. T. Simon, C. Verstuyft, and M. Mary-Krause Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 4 2009 363 375
48. R.J. Applegate, M.T. Sacrinty, W.C. Little, R.M. Santos, S.K. Gandhi, and M.A. Kutcher Incidence of coronary stent thrombosis based on academic research consortium definitions Am J Cardiol 102 6 2008 683 688
49. J.M. Siller-Matula, B. Jilma, K. Schror, G. Christ, and K. Huber Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis J Thromb Haemost 8 12 2010 2624 2641
50. J.M. Siller-Matula, A.O. Spiel, and I.M. Lang Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel Am Heart J 157 1 2009 148.e1 148.e5
51. D.J. Angiolillo, and F. Alfonso Clopidogrel-statin interaction: myth or reality? J Am Coll Cardiol 50 4 2007 296 298